Anthera's cardiology drug failure leaves analysts ambivalent on remaining SLE product
This article was originally published in Scrip
Executive Summary
The catastrophic termination of Anthera Pharmaceuticals' Phase III programme in cardiovascular disease, which saw the company's share price plummet, has left some analysts undecided on how the one remaining product in its clinical stage pipeline - blisibimod (A-623) for systemic lupus erythematosus – will fare.